These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 34553334)
1. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe. Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334 [TBL] [Abstract][Full Text] [Related]
2. Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries. Vogler S; Österle A; Mayer S Int J Equity Health; 2015 Nov; 14():124. PubMed ID: 26541292 [TBL] [Abstract][Full Text] [Related]
3. Value added medicines: what value repurposed medicines might bring to society? Toumi M; Rémuzat C J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347 [No Abstract] [Full Text] [Related]
4. Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis. Dahmani H; Fradi I; Achour L; Toumi M; J Mark Access Health Policy; 2023; 11(1):2244304. PubMed ID: 37614557 [TBL] [Abstract][Full Text] [Related]
5. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey. García-Mochón L; Espín Balbino J; Olry de Labry Lima A; Caro Martinez A; Martin Ruiz E; Pérez Velasco R Health Policy; 2019 Feb; 123(2):182-190. PubMed ID: 28420539 [TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. Kawalec P; Tesar T; Vostalova L; Draganic P; Manova M; Savova A; Petrova G; Rugaja Z; Männik A; Sowada C; Stawowczyk E; Harsanyi A; Inotai A; Turcu-Stiolica A; Gulbinovič J; Pilc A Front Pharmacol; 2017; 8():892. PubMed ID: 29326583 [No Abstract] [Full Text] [Related]
7. Patient advocacy group involvement in health technology assessments: an observational study. Single A; Cabrera A; Fifer S; Tsai J; Paik JY; Hope P Res Involv Engagem; 2021 Nov; 7(1):83. PubMed ID: 34823610 [TBL] [Abstract][Full Text] [Related]
8. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
9. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. Kamusheva M; Manova M; Savova AT; Petrova GI; Mitov K; Harsányi A; Kaló Z; Márky K; Kawalec P; Angelovska B; Lakić D; Tesar T; Draganic P; Geitona M; Hatzikou M; Paveliu MS; Männik A Front Pharmacol; 2018; 9():795. PubMed ID: 30079023 [No Abstract] [Full Text] [Related]
10. Eastern Europe: pronatalist policies and private behavior. David HP Popul Bull; 1982 Feb; 36(6):1-49. PubMed ID: 12338315 [TBL] [Abstract][Full Text] [Related]
11. Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology. Inotai A; Pékli M; Jóna G; Nagy O; Remák E; Kaló Z BMC Health Serv Res; 2012 Sep; 12():332. PubMed ID: 22999574 [TBL] [Abstract][Full Text] [Related]
12. Methods for the comparative evaluation of pharmaceuticals. Zentner A; Velasco-Garrido M; Busse R GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930 [TBL] [Abstract][Full Text] [Related]
13. Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe. Henshall CH; Dankó D; Barham L; Espín J; Felix J; Harney M; Indra P; Mestre-Ferrandiz J; de Pouvourville G; Spandonaro F; Vončina L; Wilking N Appl Health Econ Health Policy; 2023 Jul; 21(4):537-546. PubMed ID: 36897550 [TBL] [Abstract][Full Text] [Related]
14. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries. Kolasa K; Kalo Z; Zah V; Dolezal T Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552 [TBL] [Abstract][Full Text] [Related]
15. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe. Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171 [TBL] [Abstract][Full Text] [Related]
16. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Vogler S; Habl C; Bogut M; Voncina L Croat Med J; 2011 Apr; 52(2):183-97. PubMed ID: 21495202 [TBL] [Abstract][Full Text] [Related]
17. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Gulácsi L; Rotar AM; Niewada M; Löblová O; Rencz F; Petrova G; Boncz I; Klazinga NS Eur J Health Econ; 2014 May; 15 Suppl 1():S13-25. PubMed ID: 24832832 [TBL] [Abstract][Full Text] [Related]
18. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134 [TBL] [Abstract][Full Text] [Related]
19. [Risk sharing methods in middle income countries]. Inotai A; Kaló Z Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986 [TBL] [Abstract][Full Text] [Related]
20. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries. Kamusheva M; Vassileva M; Savova A; Manova M; Petrova G Front Public Health; 2018; 6():61. PubMed ID: 29556491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]